Cargando…

Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells

Amplification and/or overexpression of the human epidermal growth factor 2 (HER2) oncogene occurs in about 13–15% of invasive breast cancer and triggers breast cancer cell proliferation, survival and metastatic progression. Around half of all breast cancers with HER2 overexpression co-express hormon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thaler, Sonja, Schmidt, Marcus, Roβwag, Sven, Thiede, Gitta, Schad, Arno, Sleeman, Jonathan P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641130/ https://www.ncbi.nlm.nih.gov/pubmed/29069787 http://dx.doi.org/10.18632/oncotarget.20261

Ejemplares similares

Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2− Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2− Breast Cancer
por: Roßwag, Sven, et al.
Publicado: (2021)

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen receptor and HER2 reactivation
por: Wang, Yen-Chao, et al.
Publicado: (2011)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

RASSF1A Suppresses Estrogen-Dependent Breast Cancer Cell Growth through Inhibition of the Yes-Associated Protein 1 (YAP1), Inhibition of the Forkhead Box Protein M1 (FOXM1), and Activation of Forkhead Box Transcription Factor 3A (FOXO3A)
por: Roßwag, Sven, et al.
Publicado: (2020)

HSP90 Inhibitor, 17-DMAG, Alone and in Combination with Lapatinib Attenuates Acquired Lapatinib-Resistance in ER-positive, HER2-Overexpressing Breast Cancer Cell Line
por: Lee, Hye Jin, et al.
Publicado: (2020)

Effects of Lapatinib on HER2-Positive and HER2-Negative Canine Mammary Carcinoma Cells Cultured In Vitro
por: Leis-Filho, Antonio Fernando, et al.
Publicado: (2021)

Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor
por: Spector, Neil L., et al.
Publicado: (2015)

Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants
por: Verma, Sharad, et al.
Publicado: (2018)

Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer
por: Bahnassy, Shaymaa, et al.
Publicado: (2023)

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
por: Cristofanilli, Massimo, et al.
Publicado: (2012)

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
por: Collins, Denis M., et al.
Publicado: (2019)

Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab
por: Duchnowska, Renata, et al.
Publicado: (2017)

BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy
por: Kim, Sung-Bae, et al.
Publicado: (2019)

Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ
por: Estévez, Laura G, et al.
Publicado: (2014)

Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma
por: De Silva, Nadeera, et al.
Publicado: (2015)

Metastatic, Her-2 Amplified Lacrimal Gland Carcinoma with Response to Lapatinib Treatment
por: Dennie, Trevor
Publicado: (2015)

Th1 cytokines sensitize HER-expressing breast cancer cells to lapatinib
por: Showalter, Loral E., et al.
Publicado: (2019)

Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer
por: Leung, Wing-yin, et al.
Publicado: (2015)

Resveratrol fuels HER2 and ERα-positive breast cancer behaving as proteasome inhibitor
por: Andreani, Cristina, et al.
Publicado: (2017)

EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy
por: Evans, A H, et al.
Publicado: (2010)

3D Visualization of the Dynamic Bidirectional Talk Between ER/PR and Her2 Pathways
por: Lyv, Jiahong, et al.
Publicado: (2021)

Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib
por: Oliveras-Ferraros, Cristina, et al.
Publicado: (2011)

An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models
por: Xia, Wenle, et al.
Publicado: (2013)

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer
por: Collins, Denis, et al.
Publicado: (2017)

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells
por: Ye, Min, et al.
Publicado: (2021)

Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients
por: Duchnowska, Renata, et al.
Publicado: (2015)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
por: Cheong, E. Von, et al.
Publicado: (2021)

Lapatinib dysregulates HER2 signaling and impairs the viability of human uveal melanoma cells
por: Shu, Wenying, et al.
Publicado: (2023)

Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer
por: Soleimani Dodaran, Maryam, et al.
Publicado: (2020)

Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
por: Kim, Hwang-Phill, et al.
Publicado: (2009)

Activated estrogen receptor-mitogen-activated protein kinases cross talk confer acquired resistance to lapatinib
por: Li, Zhe, et al.
Publicado: (2015)

HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?
por: Batra, Atul, et al.
Publicado: (2020)

Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
por: Sim, Sung Hoon, et al.
Publicado: (2019)

HER2 and ERβ2 downregulate estrogen-responsive element-mediated transcription activity of ERα-positive cells in response to estrogen stimulation
por: Park, B-W, et al.
Publicado: (2005)

Effective Treatment of Solitary Pituitary Metastasis with Panhypopituitarism in HER2-Positive Breast Cancer by Lapatinib
por: Park, Youngmok, et al.
Publicado: (2016)

t-Darpp overexpression in HER2-positive breast cancer confers a survival advantage in lapatinib
por: Christenson, Jessica L., et al.
Publicado: (2015)

Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer
por: Saleem, Azeem, et al.
Publicado: (2015)

The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling
por: Hsu, Wan-Tseng, et al.
Publicado: (2018)

Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma
por: Hassan, Md. Sazzad, et al.
Publicado: (2019)

Lapatinib Suppresses HER2-Overexpressed Cholangiocarcinoma and Overcomes ABCB1– Mediated Gemcitabine Chemoresistance
por: Bai, Zhiqing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ik4i0rb02ddgvrjcko4661n89f